Compare MBRX & AMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBRX | AMS |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 11.1M |
| IPO Year | 2016 | 1995 |
| Metric | MBRX | AMS |
|---|---|---|
| Price | $2.67 | $1.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $61.00 | N/A |
| AVG Volume (30 Days) | ★ 409.6K | 114.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $19,714,000.00 |
| Revenue This Year | N/A | $6.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.81 |
| 52 Week Low | $0.26 | $1.25 |
| 52 Week High | $7.98 | $3.11 |
| Indicator | MBRX | AMS |
|---|---|---|
| Relative Strength Index (RSI) | 48.07 | 51.26 |
| Support Level | $2.12 | $1.30 |
| Resistance Level | $2.72 | $1.75 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 23.88 | 39.47 |
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.